Constitutional Risk Factors

Slide 1 · Constitutional Risk Factors

Atherosclerosis: inherited predisposition, aging and biological sex

Pathology • mechanisms and clinicopathologic interpretation

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · What this lecture should establish

Distinguish constitutional susceptibility from potentially modifiable vascular risk.

Explain monogenic and polygenic genetic contributions to atherosclerosis.

Trace age-associated vascular injury and innate immune changes, including CHIP.

Interpret sex- and menopause-associated patterns without inferring hormone-therapy benefit.

Slide 3 · Three constitutional axes of vascular risk

GENETICS

Inherited liability and family clustering

AGE

Cumulative injury plus immunobiologic change

BIOLOGICAL SEX

Different population patterns across life stages

Slide 4 · Atherosclerosis is the disease framework

Atheromas are intimal plaques with lipid-rich cores and fibrous caps.

Progressive lesions can compromise arterial flow or become thrombogenic after plaque rupture.

Constitutional determinants modify the probability of developing disease; They are not themselves plaques.

Slide 5 · From susceptibility to clinical disease

Baseline constitutional susceptibility

Lipid / vascular / inflammatory exposures

Chronic arterial wall response

Atheromatous plaque

Ischemia or acute thrombosis

Schematic sequence: Source-supported causal / pathological relations

Slide 6 · Risk factors are not all equally modifiable

Constitutional

Genetic variation / family history

Increasing age

Male sex risk-factor table

Potentially modifiable

Hyperlipidemia

Hypertension and diabetes

Cigarette smoking / inflammation

A constitutional predisposition does not eliminate the value of modifying acquired risk.

Slide 7 · Risk factors act together

Prospective studies link multiple risk characteristics to atherosclerotic burden and ischemic events.

Concurrent risk factors can have greater-than-additive effects.

Reducing acquired risk can mitigate overall risk even when baseline susceptibility remains.

Slide 8 · What makes an atheroma clinically important

1. Fibrous cap over lipid-rich core

2. Plaque encroaches on arterial lumen

3. Rupture can trigger thrombosis

4. Media weakening contributes to aneurysm risk

Schematic artery cross-section — not a histologic specimen

Slide 9 · Atherosclerosis as a response to injury

Endothelial dysfunction

Lipoprotein retention / modification

Monocytes → macrophages / foam cells

Smooth muscle / extracellular matrix response

Progressive plaque

Schematic sequence: Source-supported causal / pathological relations

Slide 10 · Read constitutional factors as susceptibility modifiers

Genetic background can alter lipid handling and vascular response.

Age reflects both accumulated lesions and changes in innate immunity.

Sex-associated population patterns vary with menopausal status and coexist with major acquired risk factors.

Slide 11 · Genetics: The family-history signal

Family history

Family history as the most important independent risk factor for atherosclerosis.

Familial clustering does not imply a single disease-causing allele.

Assessment must distinguish rare Mendelian disorders from common polygenic predisposition.

Slide 12 · Familial clustering has more than one explanation

Inherited variants

Rare high-impact disease-causing variants

Numerous common variants with small effects

Shared background susceptibility

Shared context

Dietary and behavioral exposures

Smoking patterns and activity

Household/cultural environment

Shared environment is an interpretive consideration, not a substitute for the textbook’s genetic emphasis.

Slide 13 · Genetic risk has distinct architectures

MONOGENIC

Single pathogenic genetic defect; Often large phenotype

POLYGENIC

Many common inherited alleles with small individual effects

FAMILIAL HISTORY

Clinical indicator encompassing inherited and shared influences

Slide 14 · Rare Mendelian disorders are consequential

Familial hypercholesterolemia is a prominent atherosclerosis-associated Mendelian condition.

Such disorders may markedly accelerate arterial disease in individual patients.

They explain only a small proportion of atherosclerosis cases at the population level.

Slide 15 · Familial hypercholesterolemia: Causal sequence

Loss of functional LDL receptors

Reduced hepatic LDL uptake

Elevated circulating LDL cholesterol

Accelerated lipid accumulation in arterial wall

Premature atherosclerotic disease

Schematic sequence: Source-supported causal / pathological relations

Slide 16 · LDL receptor dysfunction changes cholesterol clearance

The LDL receptor normally permits hepatic uptake and catabolism of circulating LDL.

Loss-of-function mutations reduce this clearance pathway.

Sustained elevated LDL exposure promotes initiation and progression of atherosclerotic lesions.

Slide 17 · Severe inherited LDL-receptor dysfunction

Early disease

Homozygous familial hypercholesterolemia can cause myocardial infarction before age 20.

This illustrates an extreme monogenic phenotype—not the typical age distribution.

Do not generalize the severity of homozygous disease to all familial risk.

Slide 18 · Monogenic disease versus common familial susceptibility

Mendelian

Single major inherited defect

Can produce strong clinical phenotype

Relatively uncommon explanation for all cases

Polygenic

Many susceptibility alleles

Small effects accumulate across loci

Typical basis of familial predisposition

Slide 19 · Polygenic susceptibility accumulates small effects

Numerous common alleles

Small individual contributions

Combined inherited susceptibility

Interaction with acquired exposures

Observed familial atherosclerotic risk

Schematic sequence: Source-supported causal / pathological relations

Slide 20 · Why polygenic risk is common

Relatives share portions of many genetic variants.

Individual variants often have modest effects but can combine to influence susceptibility.

A family history is compatible with many alleles rather than one Mendelian mutation.

Slide 21 · What family history can and cannot establish

Can indicate

Clustering of vascular events within relatives

A reason to consider inherited vulnerability

A clinical cue to scrutinize acquired risk

Cannot by itself establish

A specific causal gene or variant

A molecular diagnosis of hypercholesterolemia

The timing or certainty of an individual event

Slide 22 · Genetic predisposition can act through lipoproteins

Genetic changes in lipoprotein uptake or metabolism may elevate LDL.

Circulating LDL enters and accumulates in arterial intima.

Intimal LDL modification facilitates foam-cell development and inflammatory activation.

Slide 23 · From excess LDL to fatty streak

LDL retained in intima

Lipoprotein oxidation / modification

Macrophage scavenger-receptor uptake

Lipid-laden foam cells

Early fatty streak lesion

Schematic sequence: Source-supported causal / pathological relations

Slide 24 · Risk genotype and plaque phenotype are distinct

A pathogenic allele is an inherited exposure; It is not a microscopic diagnosis of plaque.

The arterial lesion reflects cumulative lipid, inflammatory, and smooth-muscle responses.

Atherosclerosis becomes clinically relevant through stenosis, plaque change, and downstream ischemia.

Slide 25 · Case 1 — striking familial susceptibility

An adolescent has markedly elevated LDL cholesterol and a strong family history of premature myocardial infarction.

Discussion prompts

1. Which constitutional axis dominates the history?

2. Which high-impact mechanism should be considered?

3. Why is the age of presentation significant?

Slide 26 · Case 1 — mechanistic interpretation

Inherited susceptibility is prominent; Evaluate a possible Mendelian lipid disorder.

Familial hypercholesterolemia illustrates impaired LDL-receptor–mediated clearance.

Premature disease is consistent with severe sustained LDL exposure; The vignette alone does not prove genotype.

Slide 27 · Genetics: Synthesis

A positive family history is an important independent risk signal.

Rare monogenic disorders can produce dramatic disease; Most familial predisposition is polygenic.

The proximate arterial injury still involves lipoprotein accumulation, inflammation, and plaque remodeling.

Slide 28 · Age is a dominant influence

Time + biology

Plaque progression typically becomes clinically manifest in middle age or later.

Aging permits prolonged accumulation of vascular injury.

Robbins also emphasizes acquired changes in innate immunity.

Slide 29 · Age gradient in myocardial infarction

5×

Myocardial infarction incidence rises fivefold between ages 40 and 60.

This textbook comparison describes a population age association.

It is not a prediction for a particular individual and should not be applied as a personalized multiplier.

Slide 30 · Atherosclerosis accumulates across decades

Early exposure

Lipoprotein deposition can begin before symptoms

Lesion development

Inflammatory and smooth-muscle responses

Plaque enlargement

Progressive luminal and wall changes

Clinical events

Later ischemia or plaque complications

Slide 31 · Clinical silence does not imply absent disease

Atherosclerotic lesions develop progressively.

A patient may remain asymptomatic before flow limitation or acute plaque complications.

Later clinical presentation therefore reflects a prolonged pathological process.

Slide 32 · One component of aging: Cumulative arterial injury

Repeated vascular exposures

Endothelial dysfunction

Intimal lipid / inflammatory response

Progressive structural plaque change

Increasing probability of clinical disease

Schematic sequence: Source-supported causal / pathological relations

Slide 33 · Aging is not simply more years of exposure

Advancing age to alterations in the innate immune system.

These alterations may modify inflammatory behavior during atherogenesis.

The age association therefore combines cumulative lesion development with acquired biology.

Slide 34 · Two complementary aging pathways

CUMULATIVE INJURY

Long-term exposure to endothelial / lipid insults

IMMUNE AGING

Acquired alteration of innate immune-cell biology

CLINICAL EXPRESSION

Greater burden and consequences of arterial plaques

Slide 35 · Clonal hematopoiesis: The defining observation

Some hematopoietic stem-cell clones acquire somatic mutations.

Specific mutations can confer a growth or survival advantage over other stem-cell clones.

The mutant clone expands and contributes circulating blood cells.

Slide 36 · CHIP develops through clonal selection

Somatic mutation in HSC

Selective advantage for mutant HSC

Expansion of mutant hematopoietic clone

Production of clone-derived immune cells

Altered inflammatory vascular milieu

Schematic sequence: Source-supported causal / pathological relations

Slide 37 · CHIP is not a diagnosis of leukemia

CHIP

Clonal hematopoiesis without defined hematologic malignancy

May be identified in otherwise apparently well adults

Associated with future hematologic risk

Atherosclerotic relevance

Clone-derived myeloid cells may be proinflammatory

Linked with cardiovascular mortality

Potential amplifier of existing lesion biology

A clonal mutation does not establish a hematologic cancer or atherosclerotic event.

Slide 38 · CHIP has two distinct clinical associations

CHIP is associated with increased risk of hematopoietic malignancy.

The textbook also describes a strong association with cardiovascular mortality.

These are separate outcomes; An association alone is not proof of mechanism in humans.

Slide 39 · Proposed inflammatory route from CHIP to plaque

Mutant hematopoietic clone

Clone-derived monocytes

Proinflammatory immune phenotype

Amplified arterial wall inflammation

Accelerated atherogenesis in animal models

Schematic sequence: Source-supported causal / pathological relations

Slide 40 · Why monocytes matter

Monocytes adhere to activated endothelium and migrate into the intima.

Intimal monocytes differentiate into macrophages.

Macrophages ingest modified lipoproteins and release inflammatory mediators.

This positions myeloid behavior at the intersection of CHIP and atherosclerosis.

Slide 41 · Inflammation links blood cells with arterial plaque

1. Endothelial activation recruits monocytes

2. Macrophages accumulate in intima

3. Lipid-filled foam cells populate lesions

4. Chronic inflammation sustains plaque remodeling

Schematic artery cross-section — not a histologic specimen

Slide 42 · What is established versus mechanistically inferred

Human association

CHIP is associated with cardiovascular mortality

CHIP is linked with hematologic malignancy risk

Association does not define an individual prognosis

Animal-model inference

Clone-derived monocytes can be proinflammatory

Inflammatory phenotype can worsen lesions

Mechanistic evidence should not be overstated as human proof

Slide 43 · An age-related vascular-risk model

Years of exposure permit plaque accumulation.

Age-associated hematopoietic clones may further influence myeloid inflammation.

Together these processes help explain why aging tracks strongly with ischemic disease.

Slide 44 · Case 2 — vascular risk in later life

An older adult has progressive coronary atherosclerosis without a recognized Mendelian lipid disorder.

Discussion prompts

1. What age-related mechanisms are relevant?

2. Why is cumulative injury not the sole explanation?

3. How should an incidental CHIP finding be interpreted?

Slide 45 · Case 2 — interpretation

Progressive vascular injury can accumulate over many years.

Innate immune alterations are an additional aging-associated mechanism.

CHIP supports an association with cardiovascular risk but does not prove that the clone caused this individual’s lesion.

Slide 46 · Age: Synthesis

Risk rises with age because atherosclerosis is progressive.

Innate immune changes provide a complementary biological explanation.

CHIP connects somatic clonal selection with proinflammatory myeloid responses and cardiovascular association.

Slide 47 · Biological sex influences atherosclerotic risk

Life stage matters

The Robbins population-level comparison changes substantially before and after menopause.

Risk patterns are group-level observations, not disease exclusion rules.

Severe acquired risk factors can override apparent premenopausal protection.

Slide 48 · Premenopausal sex-associated pattern

Premenopausal females

Relatively lower atherosclerotic complication frequency

MI generally uncommon without other strong predisposition

Risk is never zero

Age-matched males

Higher frequency of atherosclerosis and consequences comparison

Population contrast, not an individual prediction

Other risk factors still modify risk

Slide 49 · Premenopausal protection is relative

Lower atherosclerotic burden and consequences before menopause.

This comparison is with age-matched males, not with all older or younger populations.

The relationship should not be interpreted as immunity to coronary disease.

Slide 50 · When premenopausal complications do occur

DIABETES

Major acquired risk can counter baseline protection

HYPERLIPIDEMIA

High lipid exposure can accelerate lesions

SEVERE HYPERTENSION

Sustained hemodynamic stress increases vascular risk

Slide 51 · Menopause alters the epidemiologic pattern

Following menopause, the incidence of atherosclerosis-related disease rises in females.

An eventual incidence exceeding that in males.

The comparison is time- and population-dependent; Do not infer an exact crossover age from this source.

Slide 52 · Sex-associated risk varies with life stage

Before menopause

Relative protection in the population comparison

Menopausal transition

Population pattern changes

Later life

Rising disease incidence in females

Clinical interpretation

Evaluate all accompanying risk factors

Slide 53 · Estrogen protection was a hypothesis

A favorable vascular influence of estrogen was proposed to explain premenopausal patterns.

Such a biological hypothesis does not establish that prescribing estrogen prevents events.

Intervention trials are required to test clinical benefit and harm.

Slide 54 · Physiological association versus treatment effect

Observation

Premenopausal females have lower event rates

Temporal association suggests possible mechanisms

Multiple biological and acquired factors coexist

Intervention

Postmenopausal estrogen replacement was tested

Trials did not demonstrate cardiovascular benefit

Some older recipients experienced higher cardiovascular risk

Slide 55 · Menopausal hormone therapy is not vascular prevention

No prevention benefit

No cardiovascular benefit from estrogen replacement trials and increased risk in some older females.

Do not infer treatment efficacy from the premenopausal epidemiologic pattern.

Hormone therapy has separate indications and risks not evaluated in this focused lecture.

Slide 56 · Sex-associated risk must be interpreted conditionally

Premenopausal status modifies baseline probability but cannot rule out disease.

Diabetes, major lipid abnormalities, and severe hypertension remain important.

After menopause, the epidemiologic pattern changes; Clinical assessment remains multifactorial.

Slide 57 · Case 3 — challenge the protection assumption

A premenopausal adult presents with an ischemic event and has severe hyperlipidemia and diabetes.

Discussion prompts

1. Is this incompatible with Robbins’ sex-risk description?

2. Which factors undermine relative premenopausal protection?

3. Would this case support estrogen prophylaxis?

Slide 58 · Case 3 — interpretation

Relative, not absolute, protection.

Coexisting hyperlipidemia and diabetes can confer substantial atherosclerotic risk.

The clinical event does not establish any preventive role for postmenopausal estrogen replacement.

Slide 59 · Biological sex: Synthesis

Sex-associated atherosclerosis patterns depend on age and menopausal status.

Premenopausal risk remains clinically important with major acquired exposures.

Trials refute the assumption that postmenopausal estrogen therapy prevents cardiovascular events.

Slide 60 · Integrate the constitutional axes

GENOTYPE

Monogenic disease or distributed polygenic liability

AGING

Cumulative injury and immunobiological remodeling

SEX / LIFE STAGE

Population-level shifts before and after menopause

Slide 61 · A single downstream pathological pathway

Inherited / age / sex-associated susceptibility

Endothelial and metabolic influences

Lipid deposition + inflammation

Fibrous atheromatous plaque

Ischemia / rupture / thrombosis

Schematic sequence: Source-supported causal / pathological relations

Slide 62 · Predisposition and event are different outcomes

Susceptibility

Inherited alleles

Age-related processes

Sex / menopausal profile

Clinical event

Arterial plaque burden / location

Plaque disruption or critical narrowing

Thrombosis and downstream tissue injury

Slide 63 · Why modifiable factors remain relevant

Constitutional factors cannot simply be removed, but acquired exposures remain tractable.

That risk factors interact and interventions can mitigate total risk.

A risk assessment should not mistake fixed determinants for inevitable disease.

Slide 64 · A clinically useful contrast

Constitutional determinant

Principal interpretation

Potential pitfall

Family history

Inherited susceptibility; often polygenic

Assuming a unique Mendelian variant

Increasing age

Cumulative vascular injury plus immune change

Equating age with time alone

Biological sex

Life-stage-dependent epidemiologic pattern

Assuming absolute premenopausal protection

CHIP (age-linked)

Cardiovascular association; possible inflammatory mechanism

Treating association as proven individual cause

Constitutional determinant

Principal interpretation

Potential pitfall

Slide 65 · Integrated case — interpret layered risk

A 62-year-old postmenopausal adult with a family history of premature coronary disease and long-standing hypertension develops angina.

Discussion prompts

1. Which factors are constitutional?

2. Which factor is potentially modifiable?

3. What arterial lesion could underlie angina?

Slide 66 · Integrated case — answer

Age, sex/life stage, and family history are constitutional determinants.

Hypertension is a major potentially modifiable co-exposure.

An atheromatous plaque causing coronary flow limitation is one plausible substrate; Clinical findings alone do not prove plaque morphology.

Slide 67 · Five conclusions to retain

Familial history is an important independent marker of atherosclerotic susceptibility.

Rare monogenic disease contrasts with the more usual polygenic predisposition.

Aging links lesion accumulation with acquired innate immune changes.

CHIP is cardiovascular-risk-associated; Proposed inflammation is supported particularly by animal experiments.

Menopause modifies population risk, but estrogen replacement has not prevented cardiovascular events.

Slide 68 · Primary source and scope

Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th ed. (2026).

Blood Vessels: Atherosclerosis — constitutional risk factors.

Parent context: atherosclerosis, major risk factors, and mechanisms of atherogenesis.

Textbook-derived epidemiologic statements reflect the edition; no external guideline claims were added.